Today, on
Resolution on adoption of accounts and allocation of the company's result
The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet. The annual general meeting also resolved in accordance with the proposal from the Board to allocate the company's result, meaning that no dividends are paid and that unappropriated earnings are carried forward to a new account.
Discharge from liability for the members of the Board and the CEO
The annual general meeting resolved to discharge the Board members and the CEO from liability for the financial year 2021.
Election and remuneration of the Board and auditors
The annual general meeting resolved in accordance with the proposal from the Nomination Committee to re-elect
Furthermore, the annual general meeting resolved in accordance with the proposal from the Nomination Committee that remuneration to the Board shall be paid with
Finally, the annual general meeting resolved in accordance with the proposal from the Nomination Committee to re-elect
Instruction for the Nomination Committee
The annual general meeting resolved in accordance with the proposal from the Nomination Committee that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall consist of three members representing the three largest shareholders as of the last calendar day in
Resolution on approval of remuneration report
The annual general meeting resolved to approve the Board's remuneration report for the financial year 2021.
Resolution on authorization regarding issues
The annual general meeting resolved in accordance with the proposal from the Board to authorize the Board, at one or several occasions, during the time up until the next annual general meeting, with or without deviation from the shareholders' preferential rights, to resolve to issue new shares, convertibles and/or warrants. Issues may be made with or without provisions regarding payment in kind or through set-off or other provisions. The total number of shares that may be issued pursuant to the authorization (alternatively be issued through conversion of warrants and/or exercise of convertibles) shall not exceed 20,228,950 shares, which corresponds to an aggregate dilution of approximately 20 per cent calculated on the number of outstanding shares in the company. The purpose of the authorization is to enable the company to raise working capital, to execute acquisitions of companies or operating assets as well as to enable issues to industrial partners within the framework of partnerships and alliances. To the extent an issue is made with deviation from the shareholders' preferential rights, the issue should be made on market terms (subject to customary new issue discount, as applicable).
Lomma on
For more information, please contact:
This information was submitted for publication, through the agency of the contact person set out above, at
About
https://news.cision.com/nexam-chemical/r/bulletin-from-the-annual-general-meeting-in-nexam-chemical-holding-ab--publ--on-may-11-2022,c3565362
https://mb.cision.com/Main/6364/3565362/1578347.pdf
(c) 2022 Cision. All rights reserved., source